Clinical characteristics
| Characteristic . | All patients (n = 88), no. (%) of patients . | I-PET negative (n = 63), no. (%) of patients . | I-PET positive (n = 25), no. (%) of patients . | P . |
|---|---|---|---|---|
| Age | ||||
| > 60 y | 35 (40) | 28 (44) | 7 (28) | .227 |
| < 60 y | 53 (60) | 35 (56) | 18 (72) | |
| Sex | ||||
| Female | 47 (53) | 29 (46) | 18 (72) | .034 |
| Male | 41 (47) | 34 (54) | 7 (28) | |
| Ann Arbor stage | ||||
| III or IV | 59 (67) | 37 (59) | 22 (88) | .011 |
| I or II | 29 (33) | 26 (41) | 3 (12) | |
| ECOG Performance Status | ||||
| > 2 | 25 (28) | 15 (24) | 10 (40) | .189 |
| 0 to 1 | 63 (72) | 48 (76) | 15 (60) | |
| LDH | ||||
| > 450 U/L | 42 (48) | 28 (44) | 14 (56) | .354 |
| < 450 U/L | 46 (52) | 35 (56) | 11 (44) | |
| Extranodal involvement | ||||
| > 2 | 23 (26) | 13 (21) | 10 (40) | .104 |
| 0 or 1 | 65 (74) | 50 (79) | 15 (60) | |
| Age-adjusted IPI risk | ||||
| > 3 | 35 (40) | 23 (37) | 12 (48) | .344 |
| 0-2 | 53 (60) | 40 (63) | 13 (52) | |
| Bulky disease | ||||
| Yes | 27 (31) | 18 (29) | 9 (36) | .609 |
| No | 61 (69) | 45 (71) | 16 (64) | |
| Bone marrow involvement | ||||
| Yes | 20 (23) | 15 (24) | 5 (20) | .785 |
| No | 68 (77) | 48 (76) | 20 (80) | |
| Spleen involvement | ||||
| Yes | 14 (16) | 11 (17) | 3 (12) | .749 |
| No | 74 (84) | 52 (83) | 22 (88) |
| Characteristic . | All patients (n = 88), no. (%) of patients . | I-PET negative (n = 63), no. (%) of patients . | I-PET positive (n = 25), no. (%) of patients . | P . |
|---|---|---|---|---|
| Age | ||||
| > 60 y | 35 (40) | 28 (44) | 7 (28) | .227 |
| < 60 y | 53 (60) | 35 (56) | 18 (72) | |
| Sex | ||||
| Female | 47 (53) | 29 (46) | 18 (72) | .034 |
| Male | 41 (47) | 34 (54) | 7 (28) | |
| Ann Arbor stage | ||||
| III or IV | 59 (67) | 37 (59) | 22 (88) | .011 |
| I or II | 29 (33) | 26 (41) | 3 (12) | |
| ECOG Performance Status | ||||
| > 2 | 25 (28) | 15 (24) | 10 (40) | .189 |
| 0 to 1 | 63 (72) | 48 (76) | 15 (60) | |
| LDH | ||||
| > 450 U/L | 42 (48) | 28 (44) | 14 (56) | .354 |
| < 450 U/L | 46 (52) | 35 (56) | 11 (44) | |
| Extranodal involvement | ||||
| > 2 | 23 (26) | 13 (21) | 10 (40) | .104 |
| 0 or 1 | 65 (74) | 50 (79) | 15 (60) | |
| Age-adjusted IPI risk | ||||
| > 3 | 35 (40) | 23 (37) | 12 (48) | .344 |
| 0-2 | 53 (60) | 40 (63) | 13 (52) | |
| Bulky disease | ||||
| Yes | 27 (31) | 18 (29) | 9 (36) | .609 |
| No | 61 (69) | 45 (71) | 16 (64) | |
| Bone marrow involvement | ||||
| Yes | 20 (23) | 15 (24) | 5 (20) | .785 |
| No | 68 (77) | 48 (76) | 20 (80) | |
| Spleen involvement | ||||
| Yes | 14 (16) | 11 (17) | 3 (12) | .749 |
| No | 74 (84) | 52 (83) | 22 (88) |